{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:41Z","timestamp":1791335621138,"version":"4.3.1"},"reference-count":78,"publisher":"BMJ","issue":"8","funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["no grant number"],"award-info":[{"award-number":["no grant number"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["PhD grant"],"award-info":[{"award-number":["PhD grant"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A29372"],"award-info":[{"award-number":["A29372"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,10,3]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pleural mesothelioma (PM) is characterised by marked heterogeneity, both clinically in terms of survival and response to treatment, and in terms of histology and molecular status. Development of novel therapies, stratified treatment pathways and a better understanding of resistance mechanisms are urgently needed. This requires an in-depth understanding of the multiple sources of heterogeneity affecting tumour cells and the tumour microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This review, which synthesises the key studies available in the literature, provides a detailed description of the current state of the art regarding heterogeneity in PM. After an overview of the general molecular landscape and a summary of heterogeneity between patients (intertumour heterogeneity), we review sources of variation within an individual patient\u2019s tumour (intratumour heterogeneity). This section covers both the local heterogeneity classically reported in other tumours and the anatomical heterogeneity, which is more profound in PM given the large pleural surface area over which the disease develops and progresses. We also synthesise the available data on changes that develop over time (temporal heterogeneity). The various cellular and molecular sources of heterogeneity are also highlighted throughout each section, including histological variations, genomic and non-genomic molecular changes and variations in tumour, stromal and immune compartments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The solid understanding of intertumour heterogeneity recently achieved has highlighted diverse molecular and cellular landscapes. However, this knowledge has yet to be effectively translated into clinical practice (eg, diagnostic classification, treatment allocation, trial design). Further research is needed for a better comprehension of intratumour heterogeneity, including characterisation of local tumour-immune-stromal interactions, including those based on anatomical position on the pleural surface. Efforts should also include dissection of intratumour heterogeneity in patients treated by immunotherapy, development of preclinical models that adequately capture heterogeneity and the investigation of clonality and tumour evolution over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2024-222052","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:40:16Z","timestamp":1761979216000},"page":"796-805","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Intratumour, anatomical and temporal heterogeneity in mesothelioma"],"prefix":"10.1136","volume":"81","clinical-trial-number":[{"clinical-trial-number":"nct05278975","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"isrctn22929761","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2985-8326","authenticated-orcid":false,"given":"Maya","family":"Arnould","sequence":"first","affiliation":[{"name":"Centre de Recherche des Cordeliers, \"Functional Genomics of Solid Tumors\" Team, INSERM, Universit\u00e9 Paris Cit\u00e9, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D J","family":"Neilly","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-6641","authenticated-orcid":false,"given":"Kevin G","family":"Blyth","sequence":"additional","affiliation":[{"name":"Glasgow Pleural Disease Unit, Queen Elizabeth University Hospital, Glasgow, UK"},{"name":"Cancer Research UK Scotland Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5823-7404","authenticated-orcid":false,"given":"Didier","family":"Jean","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, \"Functional Genomics of Solid Tumors\" Team, INSERM, Universit\u00e9 Paris Cit\u00e9, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2026071502151573000_81.8.796.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2026071502151573000_81.8.796.2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32714-8"},{"key":"2026071502151573000_81.8.796.3","doi-asserted-by":"crossref","first-page":"107440","DOI":"10.1016\/j.lungcan.2023.107440","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"2026071502151573000_81.8.796.4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026071502151573000_81.8.796.5","article-title":"Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment","volume":"5","author":"Schmid","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"2026071502151573000_81.8.796.6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061498","article-title":"Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study","volume":"14","author":"Assi\u00e9","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026071502151573000_81.8.796.7","doi-asserted-by":"crossref","first-page":"107866","DOI":"10.1016\/j.lungcan.2024.107866","article-title":"Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04\u20132021) trial","volume":"194","author":"Bylicki","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"2026071502151573000_81.8.796.8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"2026071502151573000_81.8.796.9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","article-title":"Immunotherapy approaches for malignant pleural mesothelioma","volume":"19","author":"Fennell","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026071502151573000_81.8.796.10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/14728222.2023.2277224","article-title":"Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement","volume":"27","author":"Assi\u00e9","year":"2023","journal-title":"Expert Opin Ther Targets"},{"key":"2026071502151573000_81.8.796.11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026071502151573000_81.8.796.12","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520"},{"key":"2026071502151573000_81.8.796.13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0804"},{"key":"2026071502151573000_81.8.796.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"key":"2026071502151573000_81.8.796.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01321-1"},{"key":"2026071502151573000_81.8.796.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01541-0"},{"key":"2026071502151573000_81.8.796.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-022-01060-8","article-title":"Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma","volume":"14","author":"Creaney","year":"2022","journal-title":"Genome Med"},{"key":"2026071502151573000_81.8.796.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.100938","article-title":"Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma","volume":"4","author":"Nair","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026071502151573000_81.8.796.19","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2011-0215-RA"},{"key":"2026071502151573000_81.8.796.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.10.001"},{"key":"2026071502151573000_81.8.796.21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jtho.2021.10.022","article-title":"Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors","volume":"17","author":"Kosari","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026071502151573000_81.8.796.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.128"},{"key":"2026071502151573000_81.8.796.23","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00422","article-title":"Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026071502151573000_81.8.796.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01979-0"},{"key":"2026071502151573000_81.8.796.25","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.351"},{"key":"2026071502151573000_81.8.796.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3573"},{"key":"2026071502151573000_81.8.796.27","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12651"},{"key":"2026071502151573000_81.8.796.28","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2023-0304-RA"},{"key":"2026071502151573000_81.8.796.29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/his.14105","article-title":"Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma","volume":"77","author":"Bilecz","year":"2020","journal-title":"Histopathology"},{"key":"2026071502151573000_81.8.796.30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026071502151573000_81.8.796.31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.21037\/tlcr.2020.03.38","article-title":"Clinical significance of histologic subtyping of malignant pleural mesothelioma","volume":"9","author":"Brcic","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2026071502151573000_81.8.796.32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41379-019-0320-y","article-title":"Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas","volume":"33","author":"Dacic","year":"2020","journal-title":"Mod Pathol"},{"key":"2026071502151573000_81.8.796.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.025"},{"key":"2026071502151573000_81.8.796.34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3907"},{"key":"2026071502151573000_81.8.796.35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01293","article-title":"Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy","volume":"9","author":"Tomasetti","year":"2019","journal-title":"Front Oncol"},{"key":"2026071502151573000_81.8.796.36","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jtho.2021.05.015","article-title":"DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis","volume":"16","author":"Vandenhoeck","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026071502151573000_81.8.796.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2429"},{"key":"2026071502151573000_81.8.796.38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127310","article-title":"Disabling Mitochondrial Peroxide Metabolism via Combinatorial Targeting of Peroxiredoxin 3 as an Effective Therapeutic Approach for Malignant Mesothelioma","volume":"10","author":"Cunniff","year":"2015","journal-title":"PLoS One"},{"key":"2026071502151573000_81.8.796.39","doi-asserted-by":"crossref","first-page":"107622","DOI":"10.1016\/j.lungcan.2024.107622","article-title":"61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma","volume":"190","author":"Cunniff","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"2026071502151573000_81.8.796.40","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2024.42.16_suppl.3019","article-title":"First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE)","volume":"42","author":"Fennell","year":"2024","journal-title":"JCO"},{"key":"2026071502151573000_81.8.796.41","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101226","article-title":"MesoGraph: Automatic profiling of mesothelioma subtypes from histological images","volume":"4","author":"Eastwood","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026071502151573000_81.8.796.42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMedicine"},{"key":"2026071502151573000_81.8.796.43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133205","article-title":"The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review","volume":"13","author":"D\u00e9sage","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026071502151573000_81.8.796.44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061603","article-title":"Heterogeneity in Malignant Pleural Mesothelioma","volume":"19","author":"Oehl","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026071502151573000_81.8.796.45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.870352","article-title":"Prognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma","volume":"12","author":"Ollila","year":"2022","journal-title":"Front Oncol"},{"key":"2026071502151573000_81.8.796.46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105786","article-title":"Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study","volume":"23","author":"Mannarino","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026071502151573000_81.8.796.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.09.025"},{"key":"2026071502151573000_81.8.796.48","doi-asserted-by":"crossref","first-page":"106883","DOI":"10.1016\/j.rmed.2022.106883","article-title":"Inflammatory appearance of the parietal pleura at thoracoscopy - What does it hide?","volume":"199","author":"Madani","year":"2022","journal-title":"Respir Med"},{"key":"2026071502151573000_81.8.796.49","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jtho.2018.04.023","article-title":"New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center","volume":"13","author":"Galateau Salle","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2026071502151573000_81.8.796.50","doi-asserted-by":"crossref","first-page":"100706","DOI":"10.1016\/j.modpat.2025.100706","article-title":"Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma","volume":"38","author":"Fanaroff","year":"2025","journal-title":"Mod Pathol"},{"key":"2026071502151573000_81.8.796.51","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01816-9","article-title":"Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy","volume":"22","author":"Torricelli","year":"2023","journal-title":"Mol Cancer"},{"key":"2026071502151573000_81.8.796.52","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","article-title":"Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma","volume":"14","author":"Giotti","year":"2024","journal-title":"Cancer Discov"},{"key":"2026071502151573000_81.8.796.53","doi-asserted-by":"crossref","unstructured":"Severson DT , Freyaldenhoven S , Wadowski B , et al . Comprehensive multi-site profiling of the malignant pleural mesothelioma micro-environment identifies candidate molecular determinants of histopathologic type. Cancer Biology [Preprint] 2024. doi:10.1101\/2024.05.24.595690","DOI":"10.1101\/2024.05.24.595690"},{"key":"2026071502151573000_81.8.796.54","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J Transl Med"},{"key":"2026071502151573000_81.8.796.55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1767"},{"key":"2026071502151573000_81.8.796.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21798-w"},{"key":"2026071502151573000_81.8.796.57","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-021-00931-w","article-title":"Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma","volume":"13","author":"Meiller","year":"2021","journal-title":"Genome Med"},{"key":"2026071502151573000_81.8.796.58","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1158\/2767-9764.CRC-23-0524","article-title":"Spatial Landscape of Malignant Pleural and Peritoneal Mesothelioma Tumor Immune Microenvironments","volume":"4","author":"Ma","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026071502151573000_81.8.796.59","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/1759-7714.14981","article-title":"High density and proximity of CD8+ T cells to tumor cells are correlated with better response to nivolumab treatment in metastatic pleural mesothelioma","volume":"14","author":"Yin","year":"2023","journal-title":"Thorac Cancer"},{"key":"2026071502151573000_81.8.796.60","doi-asserted-by":"crossref","DOI":"10.1186\/1743-8977-7-5","article-title":"Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma","volume":"7","author":"Donaldson","year":"2010","journal-title":"Part Fibre Toxicol"},{"key":"2026071502151573000_81.8.796.61","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00062102"},{"key":"2026071502151573000_81.8.796.62","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1002\/cncr.32416","article-title":"Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma","volume":"125","author":"Chirieac","year":"2019","journal-title":"Cancer"},{"key":"2026071502151573000_81.8.796.63","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1278330","article-title":"Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma","volume":"6","author":"Kiyotani","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026071502151573000_81.8.796.64","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.23189","article-title":"Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways","volume":"63","author":"Jama","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"key":"2026071502151573000_81.8.796.65","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-024-00531-y","article-title":"Clonal gene signatures predict prognosis in mesothelioma and lung adenocarcinoma","volume":"8","author":"Lin","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026071502151573000_81.8.796.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2017.09.007"},{"key":"2026071502151573000_81.8.796.67","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1200650","article-title":"Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma","volume":"5","author":"Farahmand","year":"2023","journal-title":"Front Toxicol"},{"key":"2026071502151573000_81.8.796.68","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00388","article-title":"The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models","volume":"10","author":"Blanquart","year":"2020","journal-title":"Front Oncol"},{"key":"2026071502151573000_81.8.796.69","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000055"},{"key":"2026071502151573000_81.8.796.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.09.044"},{"key":"2026071502151573000_81.8.796.71","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356146","article-title":"Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma","volume":"6","author":"Terra","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026071502151573000_81.8.796.72","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann Oncol"},{"key":"2026071502151573000_81.8.796.73","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143611","article-title":"Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients","volume":"15","author":"Cedres","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026071502151573000_81.8.796.74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1026185","article-title":"Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics","volume":"13","author":"Stern","year":"2022","journal-title":"Front Immunol"},{"key":"2026071502151573000_81.8.796.75","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222054"},{"key":"2026071502151573000_81.8.796.76","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0583-3"},{"key":"2026071502151573000_81.8.796.77","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-024-00471-5","article-title":"A systematic pan-cancer study on deep learning-based prediction of multi-omic biomarkers from routine pathology images","volume":"4","author":"Arslan","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"2026071502151573000_81.8.796.78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02857-3"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2024-222052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:15:51Z","timestamp":1784106951000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2024-222052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":78,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/thorax-2024-222052"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2024-222052","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}